FDA Extends Review of Somaxon Pharmaceuticals' New Drug …
Somaxon cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements. For example, statements regarding the potential
approval of the NDA for Silenor and the potential commercialization of
Silenor are forward looking statements. The inclusion of
forward-looking statements should not be regarded as a representation by
Somaxon Read the rest of this entry »